From science to patients: Mechanisms of organ benefit with SGLT2 inhibition
State of the art lecture: NASH, disease burden and new opportunities

Co-Chair: Nayyar Iqbal (AstraZeneca)

14:30 – 14:35WelcomeElisabeth Björk (AstraZeneca)
Nayyar Iqbal (AstraZeneca)
14:35 – 14:50Role of water conservation and metabolism in SGLT2 inhibitor mediated organ protectionJens Marc Titze (SGP)
14:50 – 15:10Cracking the code in CKD: Mechanisms of renoprotectionHiddo Heerspink (NLD)
15:10 – 15:30SGLT2 inhibitors in HF: Piecing together the puzzle of preserved ejection fractionSanjiv Shah (USA)
15:30 – 15:40Panel discussionAll faculty
15:40 – 15:55State of art lecture: NASH, disease burden and new opportunities – Emerging new modalities to manage NASHArun Sanyal (USA)
15:55 – 16:00Closing remarksRegina Fritsche-Danielson (AstraZeneca)